Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie’s Disease

Overview

Two recent studies have identified low levels of serum testosterone in association with Peyronie's Disease (PD), with a significant correlation noted between severity of testosterone deficiency and severity of curvature. The study hypothesis is to determine whether treatment with testosterone may help men with PD and penile curvature.

Full Title of Study: “An Open-Label, Nine-Month Randomized Controlled Study of Testosterone (Testopel) Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie’s Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 7, 2013

Interventions

  • Drug: Vitamin D2
    • oral softgel 2000 IU once daily 9 months
  • Drug: Vitamin E
    • oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily 1 softgel of 200 IU daily 9 months
  • Drug: Testosterone Pellets
    • subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months

Arms, Groups and Cohorts

  • Active Comparator: Vitamin D and E
    • Oral Vitamin D and E alone in men with penile curvature due to PD.
  • Active Comparator: Testosterone Pellets and Vitamin D and E
    • Testosterone in combination with oral Vitamin D an E supplementation in men with penile curvature due to PD.

Clinical Trial Outcome Measures

Primary Measures

  • penile curvature
    • Time Frame: 9 months
    • The primary outcome to be assessed will be the change in penile curvature from baseline.

Secondary Measures

  • sexual function
    • Time Frame: 9 months
    • Secondary outcomes will incluce overall satisfaction with sexual function (patient satisfaction with treatment, quality of erections and quality of life).

Participating in This Clinical Trial

Inclusion Criteria

  • acquired penile curvature of > 30 degrees and < 90 degrees associated with palpable penile plaque on physical examination – onset of curvature within 18 months prior to signing consent form – serum TT < 500 ng/dl at the screening visit Exclusion Criteria:

  • prior history of treatment for PD that includes intra-lesional injections, topical creams, or surgery – prior treatment with oral therapy at least 2 weeks prior to signing consent form (e.g. Potaba, Vitamin E, colchicines) will be acceptable for inclusion – prior history of treatment for testosterone deficiency – presence of dense calcified plaque by US or plain radiograph – taking the medication Coumadin – hypersensitivity to testosterone, stearic acid, or polyvinyl pyrolidone (the constituents of Testopel) – unable to achieve adequate erection with penile injection to access degree of curvature – undergone definitive treatment for prostate cancer, bladder cancer, or other pelvic malignancies including surgery, external beam radiation therapy, brachytherapy, cryotherapy. – prior history of prostate cancer, hematologic disorders, chronic liver disease including cirrhosis and hepatitis C, disorders affecting the immune system, including infection with human immunodeficiency virus, or psychiatric disorders including major depression, schizophrenia, bipolar disease – history of cerebrovascular accident, history of deep venous thrombosis within the past 5 years or history of untreated or severe sleep apnea – PSA > 4.0 ng/dL at the screening visit, unless prostate cancer has been excluded to the investigator's satisfaction – clinically significant abnormal lab results that would put the subject at increased risk or compromise the integrity of the study data, in the opinion of the investigator – received any other investigational drug within 30 days

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Men’s Health Boston
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dr. Abraham Morgentaler, Associate Clinical Professor of Urology Harvard Medical School – Men’s Health Boston
  • Overall Official(s)
    • Abraham Morgentaler, MD, Principal Investigator, Men’s Health Boston

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.